Further characterization of a CNS adenosine A2a receptor ligand [11C]KF18446 with in vitro autoradiography and in vivo tissue uptake

Annals of Nuclear Medicine

Volumn 14, Issue 2, 2000, Pages 81-89

  Ishiwata, Kiichi ^a   Ogi, Nobuo ^a,b   Shimada, Junichi ^c   Nonaka, Hiromi ^c   Tanaka, Akira ^b   Suzuki, Fumio ^c   Senda, Michio ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Adenosine A2a receptor; PET; Striatum; 11C KF18446

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4,5 TRIMETHOXYSTYRYL) 1,3,7 TRIMETHYLXANTHINE; ADENOSINE A2A RECEPTOR ANTAGONIST; CARBON 11; KF 18446; LIGAND; METHYL IODIDE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; LIGAND BINDING; MALE; NEUROLOGIC DISEASE; NEURORADIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; AUTORADIOGRAPHY; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CORPUS STRIATUM; HUMANS; LIGANDS; MALE; MICE; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; TOMOGRAPHY, EMISSION-COMPUTED; XANTHINES;

EID: 0034115544     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988585     Document Type: Article

References (49)

1. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 46: 143-156, 1994.
2. Palmer TM, Stiles GL. Adenosine receptors. Neuropharmacology 34: 683-694, 1995.
3. 2A receptors. Trends Pharmacol Sci 17: 364-372, 1996.
4. 3H]adenosine. Eur J Pharmacol 73: 109-110, 1981.
5. 3H]cyclohexyl-adenosine. J Neurosci 2: 1230-1241, 1982.
6. Fastbom J, Pazos A, Palacios JM. The distribution of adenosine A1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22: 813-826, 1987.
7. 1 adenosine receptor regional density in the mouse brain: a quantitative autoradiographic study. Neuroscience 56: 711-716, 1993.
8. Fastbom J, Pazos A, Probst A, Palacios JM. Adenosine A1 receptors in the human brain: a quantitative autoradiographic study. Neuroscience 22: 827-839, 1987.
9. Svenningsson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 27: 322-335, 1997.
10. 3H]NECA in rat striatal membranes. Mol Pharmacol 29: 331-346, 1986.
11. 3H]-CGS 21680. Eur J Pharmacol 168: 243-246, 1989.
12. 3H]-CGS21680 as a ligand. Naunyn Schmiedebergs Arch Pharmacol 342: 85-89, 1990.
13. 3H]CGS 21680 to rat cortex differs from its binding to rat striatum. Eur J Pharmacol 247: 103-110, 1993.
14. 2A receptors in the rat hippocampus. Brain Res 649: 208-216, 1994.
15. 2A receptors. Naunyn Schmiedebergs Arch Pharmacol 353: 261-271, 1996.
16. 3H]CGS 21680 binding sites in the rat striatum and cortex. Br J Pharmacol 114: 537-543, 1995.
17. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 34: 393-403, 1995.
18. 2 receptor mRNA in the human brain. Neurosci Lett 130: 177-181, 1991.
19. 2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res 631: 161-166, 1993.
20. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience 42: 697-706, 1991.
21. Mally J, Stone TW. Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol Ther 72: 243-250, 1996.
22. Guieu R, Couraud F, Pouget J, Sampieri F, Bechis G, Rochat H. Adenosine and the nervous system: clinical implications. Clin Neuropharmacology 19: 459-474, 1996.
23. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 133: 107-120, 1997.
24. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In Pharmacological Bases of Therapeuitics (Eds. Goodman GA, Rall TW, Nies AS, Taylor P), Pergamon, New York, pp. 383-435, 1990.
25. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63: 765-773, 1994.
26. 2 antagonists. J Med Chem 35: 2342-2345, 1992.
27. 2a adenosine receptor antagonists. Current Med Chem 2: 707-722, 1995.
28. Müller CE, Stein B. Adenosine receptor antagonists: structures and potential therapeutic applications. Current Pharmaceut Design 2: 501-530, 1996.
29. Poulsen SA, Quinn RJ. Adenosine receptors: new opportunities for future drugs. Bioorg Med Chem 6: 619-641, 1998.
30. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276: 398-404, 1996.
31. 2a selective adenosine receptor antagonist. Br J Pharmacol 115: 1096-1102, 1995.
32. 2a adenosine receptor. Mol Pharmacol 48: 970-974, 1995.
33. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117: 1381-1386, 1996.
34. 2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 70: 1210-1216, 1998.
35. 2A antagonist. Appl Radiat Isot 47: 507-511, 1996.
36. 2a receptor ligand. J Nucl Med 39: 498-503, 1998.
37. 2a receptors. The 12th International Symposium on Radiopharmaceutical Chemistry held in June 15-19, 1997, in Uppsala, Sweden.
38. 2a receptor ligand. J Nucl Med 41: 345-354, 2000.
39. 2a). Drug Develop Res 45: 312-323, 1998.
40. 2-adenosine antagonist in vitro and in vivo. FEBS Lett 323: 141-144, 1993.
41. Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem 33: 2240-2254, 1990.
42. 1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. J Med Chem 35: 3066-3075, 1992.
43. 2A-selective adenosine receptor antagonists. J Med Chem 40: 3496-4405, 1997.
44. 11C]nemonapride. Nucl Med Biol 26: 291-296, 1999.
45. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647, 1995.
46. 2 antagonist, (E)-1,3-dipropyl-8-(3,4- dimethoxystyryl)-7-methylxanthine. J Med Chem 36: 3731-3733, 1993.
47. 2 receptor antagonist. Eur J Pharmacol 267: 335-341, 1994.
48. oct, from structures. Chem Rev 93: 1281-1308, 1993.
49. 3H]-CGS 21680 in the rat brain. Naunyn Schmiedsbergs Arch Pharmacol 354: 539-541, 1996.